Baidu
map

Dig Liver Dis: 生物制剂使用时小肠克罗恩病狭窄成形术后早期复发的影响因素

2019-05-21 不详 MedSci原创

存在肠腔狭窄的患者经常会行狭窄成形术来缓解梗阻情况,但是在狭窄部位的克罗恩病早期易于复发,因此,本项研究的目的是探究原发性狭窄成形术后早期再次手术复发的危险因素。

背景
存在肠腔狭窄的患者经常会行狭窄成形术来缓解梗阻情况,但是在狭窄部位的克罗恩病早期易于复发,因此,本项研究的目的是探究原发性狭窄成形术后早期再次手术复发的危险因素。

方法
研究人员收集了从2000年开始,接受了狭窄成形术以及随后在狭窄成形部位再次发生克罗恩病的再次手术的患者资料。进行单变量和多变量线性回归模型以分析复发时间与自变量之间的关系。

结果
本项研究共纳入了59名患者。中位复发时间为4.5年(0.7-12.6)。在多变量线性回归分析中,早期复发与初次手术前使用生物制剂(-2.69,p <0.0001)和回肠疾病位置显着相关(-1.61,p = 0.017)。

结论
克罗恩病在回肠中段的位置以及手术前使用生物制剂是狭窄成形手术后早期复发的有力预测因素。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2004722, encodeId=82512004e2262, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Apr 01 04:14:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013010, encodeId=3df32013010cc, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 16 06:14:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825999, encodeId=e3bd1825999da, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Mon Sep 30 00:14:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756992, encodeId=ecde1e5699265, content=<a href='/topic/show?id=929f5936375' target=_blank style='color:#2F92EE;'>#早期复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59363, encryptionId=929f5936375, topicName=早期复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5bd37287806, createdName=124985dbm18(暂无昵称), createdTime=Tue Apr 28 04:14:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465588, encodeId=3aff146558802, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Thu May 23 10:14:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2004722, encodeId=82512004e2262, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Apr 01 04:14:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013010, encodeId=3df32013010cc, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 16 06:14:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825999, encodeId=e3bd1825999da, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Mon Sep 30 00:14:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756992, encodeId=ecde1e5699265, content=<a href='/topic/show?id=929f5936375' target=_blank style='color:#2F92EE;'>#早期复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59363, encryptionId=929f5936375, topicName=早期复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5bd37287806, createdName=124985dbm18(暂无昵称), createdTime=Tue Apr 28 04:14:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465588, encodeId=3aff146558802, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Thu May 23 10:14:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2004722, encodeId=82512004e2262, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Apr 01 04:14:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013010, encodeId=3df32013010cc, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 16 06:14:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825999, encodeId=e3bd1825999da, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Mon Sep 30 00:14:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756992, encodeId=ecde1e5699265, content=<a href='/topic/show?id=929f5936375' target=_blank style='color:#2F92EE;'>#早期复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59363, encryptionId=929f5936375, topicName=早期复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5bd37287806, createdName=124985dbm18(暂无昵称), createdTime=Tue Apr 28 04:14:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465588, encodeId=3aff146558802, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Thu May 23 10:14:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2004722, encodeId=82512004e2262, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Apr 01 04:14:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013010, encodeId=3df32013010cc, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 16 06:14:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825999, encodeId=e3bd1825999da, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Mon Sep 30 00:14:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756992, encodeId=ecde1e5699265, content=<a href='/topic/show?id=929f5936375' target=_blank style='color:#2F92EE;'>#早期复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59363, encryptionId=929f5936375, topicName=早期复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5bd37287806, createdName=124985dbm18(暂无昵称), createdTime=Tue Apr 28 04:14:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465588, encodeId=3aff146558802, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Thu May 23 10:14:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2004722, encodeId=82512004e2262, content=<a href='/topic/show?id=4e8a5400816' target=_blank style='color:#2F92EE;'>#成形术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54008, encryptionId=4e8a5400816, topicName=成形术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fb6449, createdName=ZGMFX24A, createdTime=Wed Apr 01 04:14:00 CST 2020, time=2020-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013010, encodeId=3df32013010cc, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Fri Aug 16 06:14:00 CST 2019, time=2019-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1825999, encodeId=e3bd1825999da, content=<a href='/topic/show?id=6191692233a' target=_blank style='color:#2F92EE;'>#生物制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69223, encryptionId=6191692233a, topicName=生物制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93e223, createdName=bluefate121, createdTime=Mon Sep 30 00:14:00 CST 2019, time=2019-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756992, encodeId=ecde1e5699265, content=<a href='/topic/show?id=929f5936375' target=_blank style='color:#2F92EE;'>#早期复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59363, encryptionId=929f5936375, topicName=早期复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5bd37287806, createdName=124985dbm18(暂无昵称), createdTime=Tue Apr 28 04:14:00 CST 2020, time=2020-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465588, encodeId=3aff146558802, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Thu May 23 10:14:00 CST 2019, time=2019-05-23, status=1, ipAttribution=)]

相关资讯

IBD: 克罗恩病维持治疗期间阿达木单抗药物水平升高与生物学缓解相关

阿达木单抗是克罗恩病的有效治疗药物。有关阿达木单抗药物水平与肠道炎症的血清/粪便标志物之间关系还不清楚。因此,本项研究的目的是评估阿达木单抗水平与维持治疗期间生物学缓解之间的关系。

JCC: 静脉注射造影剂在克罗恩病活动超声评估中的作用

据报道,对比增强超声[CEUS]在使用内窥镜检查作为参考标准预测疾病活动方面优于彩色多普勒成像[CDI]。本项研究的目的是确定患有克罗恩病[CD]的患者,在CEUS检查之前进行CDI检查是否有助于确定何时注射造影剂而不减少CEUS的诊断效能。

JCC: 腔内对比增强超声可用来高效检测克罗恩病脓肿相关的穿透性病变

穿透性病变是克罗恩病[CD]常见的并发症。确定瘘管的存在和位置对于确定适当的治疗策略是至关重要的。本项研究的目的是评估腔内对比增强超声[IC-CEUS]用于检测CD患者脓肿相关的瘘管准确性。

Digest Liver Dis: 克罗恩病患者肠道切除术后一年内预防性药物治疗的生活质量改善情况分析

接受肠切除术的克罗恩病(CD)患者术后接受预防性药物治疗后生活质量改善情况究竟是怎样的还没有文献进行研究,因此,本项研究旨在探究这其中的关系。

Dig Liver Dis: 影响IBD患者维生素D缺乏的因素分析

维生素D缺乏症在炎性肠病(IBD)中普遍存在,并且可能与疾病活动有关。因此,本研究评估了意大利IBD患者队列中的维生素D(VitD)状态,并调查了VitD缺乏的危险因素及其与疾病活动的相关性。

JCC: Ustekinumab治疗难治性克罗恩病的儿科患者的疗效分析

Ustekinumab [UST]可有效治疗中重度克罗恩病患者[CD]。关于其在儿童中使用的数据很少。因此,本项研究旨在评估中重度CD患儿对UST的反应。

Baidu
map
Baidu
map
Baidu
map